1. Home
  2. ALT vs BUI Comparison

ALT vs BUI Comparison

Compare ALT & BUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • BUI
  • Stock Information
  • Founded
  • ALT 1997
  • BUI 2011
  • Country
  • ALT United States
  • BUI United States
  • Employees
  • ALT N/A
  • BUI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • BUI Trusts Except Educational Religious and Charitable
  • Sector
  • ALT Health Care
  • BUI Finance
  • Exchange
  • ALT Nasdaq
  • BUI Nasdaq
  • Market Cap
  • ALT 327.4M
  • BUI N/A
  • IPO Year
  • ALT N/A
  • BUI N/A
  • Fundamental
  • Price
  • ALT $3.89
  • BUI $25.78
  • Analyst Decision
  • ALT Strong Buy
  • BUI
  • Analyst Count
  • ALT 6
  • BUI 0
  • Target Price
  • ALT $17.40
  • BUI N/A
  • AVG Volume (30 Days)
  • ALT 2.3M
  • BUI 59.8K
  • Earning Date
  • ALT 11-11-2025
  • BUI 01-01-0001
  • Dividend Yield
  • ALT N/A
  • BUI 6.79%
  • EPS Growth
  • ALT N/A
  • BUI N/A
  • EPS
  • ALT N/A
  • BUI 2.75
  • Revenue
  • ALT $20,000.00
  • BUI N/A
  • Revenue This Year
  • ALT N/A
  • BUI N/A
  • Revenue Next Year
  • ALT $761,880.20
  • BUI N/A
  • P/E Ratio
  • ALT N/A
  • BUI $7.77
  • Revenue Growth
  • ALT N/A
  • BUI N/A
  • 52 Week Low
  • ALT $2.90
  • BUI $18.73
  • 52 Week High
  • ALT $11.16
  • BUI $24.22
  • Technical
  • Relative Strength Index (RSI)
  • ALT 59.99
  • BUI 26.74
  • Support Level
  • ALT $3.56
  • BUI $26.43
  • Resistance Level
  • ALT $3.72
  • BUI $27.25
  • Average True Range (ATR)
  • ALT 0.18
  • BUI 0.35
  • MACD
  • ALT 0.04
  • BUI -0.18
  • Stochastic Oscillator
  • ALT 76.34
  • BUI 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: